Andrew, thanks for correcting me. Baxter now has a product, albeit an insanely expensive oneto produce. Once this product and pher02 get to market(we hope), pher02 would win hands down on price, all other things being equal
(if that is possible). As far as Poyheme, Northfield's product, I have no data to truly see its efficacy and safety. I will try to dig that up. I can say that they have a nice head start on everyone. However, because their product is based on human blood, albeit outdated, they will run into supply problems at times , will have some element of infectious risk and tissue rejection.You cannot filter out EVERYTHING, no matter what the press releases say....Also, there will be A LOT of resistance from the public about the use of a product based on OUTDATED HUMAN BLOOD. I can tell ou from experience that parents certainly get very anxious when you mention transfusion of blood and blood products to their kid. They are deathly afraid of side effects. Now, how do you think they will react when you tell them that their kid will get a product from OUTDATED blood? They will be nuts with fear, and explanantions of the cleaning process, etc. wont matter. I think Northfield will need to do one hell of a pr job on the public to convince them that this product is SAFE. IMHO, of course,but think about it, everyone.Would you want your loved one getting this product without knowing the degree of greater safety this product provides over unexpired human blood?
BTW, only 100 people have been given Polyheme to this point, with 250 more to get in phase 3 trials>I would need to see the statistical significance of the data before passing judgement on the product.You cant simply trust a press release.
|
